56th Annual Meeting
Tentative Program Schedule
Please note that this schedule is subject to change. The Program Book distributed at the Annual Meeting will have final information on dates, times, and speakers for each presentation.


New Research Poster 3 (open)
New Research Poster Session 3

Thursday, October 30, 2008: 11:30 AM-2:00 PM
River Exhibition Hall
Level 1
Sheraton Chicago Hotel & Towers
 
3.1
First-Dose Pharmacokinetics of Lithium Carbonate in Children and Adolescents
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Cornelia Landersdorfer, Ph.D.
Vivian Kafantaris, M.D. The Zucker Hillside Hospital, Glen Oaks, NY
Mani N. Pavuluri, M.D., Ph.D. Institute for Juvenile Research, University of Illinois at Chicago, Chicago, IL
Nora K. McNamara, M.D.
Jon McClellan, M.D. University of Washington, Seattle, WA
Jean Frazier, M.D. Cambridge Health Alliance, Cambridge, MA
Michael S. Wilson, M.D.
Linmarie Sikich, M.D. University of North Carolina at Chapel Hill, Chapel Hill, NC
Robert A. Kowatch, M.D., Ph.D. Children's Hospital, Cincinnati, OH
Jacqui Lingler, B.S.
Jon Faber, M.A.
Perdita Taylor-Zapata, M.D.
William Jusko, Ph.D.
 
3.2
Six-Month Double-Blind Escitalopram Treatment of Depressed Adolescents
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Anjana Bose, Ph.D. Harborside Financial Center, Jersey City, NJ
Dennis Aquino, Ph.D.
Andrew Korotzer, Ph.D.
Stavros Tourkodimitris, Ph.D. Forest Labs, Jersey City, NJ
 
3.3
Safety and Efficacy of Ziprasidone in Pediatric Bipolar Disorder
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Paul P. Wang, M.D.
Balarama Gundapaneni, M.S.
Mark Versavel, M.D., M.B.A., Ph.D. Pfizer Inc, New London, CT
 
3.4
Long-Term Safety and Tolerability of Ziprasidone in Children and Adolescents with Bipolar Disorder
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
Paul P. Wang, M.D.
Mary Bachinsky, M.S.C. Pfizer, Inc, New London, CT
Balarama Gundapaneni, M.S.
Mark Versavel, M.D., M.B.A., Ph.D. Pfizer Inc, New London, CT
 
3.5
Parental Attitudes towards Pediatric Antidepressant Use and Psychotherapy
Jack H. Stevens, Ph.D. Ohio State University, Columbus, OH
William Gardner, Ph.D.
Wei Wang, M.S.
Ling Fan, M.P.H.
Michael Edwards, Ph.D.
John V. Campo, M.D. Nationwide Children's Hospital; The Ohio State University, Columbus, OH
 
3.6
The Drug Attitude Inventory in Adolescents: Factor Structure and Association with Adherence
Lisa D. Townsend, M.A., M.S.W. Case Western Reserve University, South Euclid, OH
Jerry Floersch, Ph.D. Case Western Reserve University, Cleveland, OH
Derrick A. Kranke, M.A. Case Western Reserve University, Shaker Heights, OH
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
 
3.7
Efficacy of Aripiprazole against Hostility in Adolescent Patients with Schizophrenia: Data from a Randomized, Placebo-Controlled Clinical Trial
Adelaide Robb, M.D. Children's National Medical Center, Washington, DC
William Carson, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Margaretta Nyilas, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Mirza Ali, Ph.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Rockville USA
Robert D. McQuade, Ph.D.
Robert A. Forbes, Ph.D. Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ
Taro Iwamoto, Ph.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Sheila Assuncao-Talbott, M.D., Ph.D.
Richard Whitehead, B.S. Otsuka America Pharmaceutical, Inc., Rockville, MD
Andrei Pikalov, M.D., Ph.D. Otsuka America Pharmaceutical, Inc., Rockville, MD
 
3.8
Efficacy of Sertraline in Childhood Posttraumatic Stress Disorder
Adelaide Robb, M.D. Children's National Medical Center, Washington, DC
Jeanette Cueva, M.D. , New York, NY
Jonathan Sporn, M.D.
Ruoyong Yang, Ph.D.
Doug Vanderburg, M.D., M.P.H. Pfizer, Inc., New York, NY
 
3.9
Post Traumatic Stress Symptoms in Youth with First Episode Bipolar Disorder
Jeffrey R. Strawn, M.D. University of Cincinnati, Cincinnati, OH
Caleb Adler, M.D. University of Cincinnati, Cincinnati, OH
David E. Fleck, Ph.D.
Stephen M. Strakowski, M.D.
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
 
3.10
A Previous Episode of Acute Stress Disorder Does Not Increase the Prevalence of Posttraumatic Stress Disorder in Children with Burn Injury
Walter Meyer, M.D. University of Texas, Medical Branch, Galveston, TX
Laura Rosenberg, Ph.D.
Marta Rosenberg, Ph.D.
Sherri Sharp, Ph.D.
Lisa Richardson, M.A.
Charles E. Holzer, Ph.D.
 
3.11
Efficacy of Cognitive Behavioral Therapy in the Treatment of Pediatric Posttraumatic Stress Disorder
Joanna Kowalik, M.D. MIHS/MedPro, Mesa, AZ
David Drachman, Ph.D.
Jacob Venter, M.D. , Boston, MA
Gilbert Ramos, M.A.
 
3.12
Psychosocial Impact of August 2007 Fire Disaster on Children and Adolescents in Peloponnesus, Greece
Gerasimos A. Kolaitis, M.D. Department of Child Psychiatry, Athens, Attica
Chara Tzavara, M.D.
Vasiliki Moulla, Ph.D.
Vasiliki Ntre
Helen Sotiropoulou
Krystalia Paflia
Konstantina Argyrou
Katerina Kotsirilou
Stella Charitaki, M.D.
Vasiliki Leventakou, M.S.
Charisios Asimopoulos, Ph.D.
John Tsiantis, M.D.
Vlasis Tomaras, M.D.
 
3.13
Resilience among Childhood Abuse Survivors with Posttraumatic Stress Disorder: Attachment Status Moderates Depression Risk and Severity Following Adversity
Anthony Charuvastra, M.D. New York University Child Study Center, New York, NY
Marylene Cloitre, Ph.D.
Patty Zorbas, M.A.
 
3.14
Language, Behavior, and Mental Health: Pathways from Age 5 to Early Adulthood
E.B. Brownlie, Ph.D.
Joseph Beitchman, M.D. Centre for Addiction & Mental Health, Toronto, ON
 
3.15
Moderators and Mediators of Fluoxetine Treatment Response for Children with Comorbid Depression and Substance Use Disorders
Kelly M. Christian, B.S. University Hospitals Case Medical Center, Cleveland, OH
Maria Pagano, Ph.D.
Christine Demeter, M.A. Case Western Reserve University, Cleveland, OH
Nora K. McNamara, M.D.
Denise Bedoya, M.A.
Jacqui Lingler, B.S.
Jon Faber, M.A.
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
 
3.16
What Predicts Future Substance Use Disorders among Youth with Bipolar Disorder?
Benjamin I. Goldstein, M.D., Ph.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Michael Strober, Ph.D.
Boris Birmaher, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
David Axelson, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Tina R. Goldstein, Ph.D. University of Pittsburgh, Pittsburgh, PA
Neal D. Ryan, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Martin Keller, M.D.
 
3.17
Family Environment and Suicidality among Bipolar Youth
Tina R. Goldstein, Ph.D. University of Pittsburgh, Pittsburgh, PA
Nicole Sinwell
Boris Birmaher, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
David Axelson, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Benjamin I. Goldstein, M.D., Ph.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Neal D. Ryan, M.D. Western Psychiatric Institute and Clinic, Pittsburgh, PA
Michael Strober, Ph.D.
Jeffrey I. Hunt, M.D. E. P. Bradley Hospital, Warren Alpert Medical School of Brown University, E. Providence, RI
Martin Keller, M.D.
 
3.18
An Investigation of Pediatric Bipolar Patients with and without ADHD Using Baddeley's Multi-Component Model of Working Memory
Tricia Hahn, Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC
Thomas W. Frazier II, Ph.D. Children's Hospital, Cleveland Clinic, Cleveland, OH
Stephen Hooper, Ph.D.
John P. Hatch, Ph.D. The University of Texas Health Science Center at San Antonio, San Antonio, TX
Miloslav Kopecek, M.D.
Rene L. Olvera, M.D. University of Texas Health Science Center Department of Psychiatry, San Antonio, TX
Giovana Zunta-Soares, M.D.
Steven R. Pliszka, M.D. University of Texas Health Science Center at San Antonio, San Antonio, TX
Eric A. Youngstrom, Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC
Jair C. Soares, M.D.
 
3.19
Suicidal Ideation in Children with Chronic Epilepsy
Jana E. Jones, Ph.D. University of Wisconsin School of Medicine and Public Health, Madison, WI
Prabha Siddarth, Ph.D. University of California at Los Angeles, Los Angeles, CA
Suresh Gurbani, M.D. Kaiser Permanente Orange County, Anaheim, CA
Rochelle Caplan, M.D. University of California at Los Angeles Neuropsychiatric Hospital, Los Angeles, CA
 
3.20
Child BP-I: Predictors of 8-Year Outcome and Prospective Continuity with Adult BP-I
Barbara Geller, M.D. Washington University in St. Louis, St. Louis, MO
Rebecca Tillman, M.S. Washington University in St. Louis, St. Louis, MO
Kristine Bolhofner, B.S.
Betsy Zimerman, M.A. Washington University in St. Louis, St. Louis, MO
 
3.21
Newly Diagnosed Bipolar Disorder: Treatment Implications
Gabrielle A. Carlson, M.D. SUNY at Stony Brook, Stony Brook, NY
Mark Olfson, M.D.
Tobias Gerhard, Ph.D.
Cecilia Huang, Ph.D.
Stephen Crystal, Ph.D.
 
3.22
Possible Interaction among BDNF Genotype, Family Environment, and Brain N-Acetyl-Aspartate Levels in Pediatric Bipolar Disorder
Megan F. Joseph, M.A.
Eric A. Youngstrom, Ph.D. University of North Carolina at Chapel Hill, Chapel Hill, NC
Sheila Caetano, M.D.
John P. Hatch, Ph.D. The University of Texas Health Science Center at San Antonio, San Antonio, TX
Rene L. Olvera, M.D. University of Texas Health Science Center Department of Psychiatry, San Antonio, TX
M. Consuelo Walss-Bass, Ph.D.
Mark Nicoletti, M.S.C.
Steven R. Pliszka, M.D. University of Texas Health Science Center at San Antonio, San Antonio, TX
Michael A. Escamilla, M.D.
Jair C. Soares, M.D.
 
3.23
A Double-Blind Placebo-Controlled Study of Quetiapine for Youth with Depression Associated with Bipolar Disorder
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
Kiki Chang, M.D. Stanford University School of Medicine, Stanford, CA
Meghan E. Howe, M.S.W. Stanford University, Stanford, CA
Holly Bryan, B.A.
Caleb Adler, M.D. University of Cincinnati, Cincinnati, OH
Manasi Rana, M.D. , Palo Alto, CA
Jeffrey A. Welge, Ph.D. University of Cincinnati College of Medicine, Cincinnati, OH
Stephen M. Strakowski, M.D.
 
3.24
Safety and Tolerability of Quetiapine in Children and Adolescents with Bipolar I Disorder and Adolescents with Schizophrenia: A 26-Week, Open Label Study
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Willie Earley , Wilmington, DE
Jill Stankowski, M.S.
Sanjeev Pathak, M.D.
 
3.25
Maintenance Treatment of Adolescent Bipolar Disorder: A 48-Week Open Study of the Effectiveness and Tolerability of Quetiapine
Anne C. Duffy, M.D., FRCPC McGill University, Westmount, PQ
Rob Milin, M.D.
Paul Grof, M.D.
 
3.26
Cardiovascular Effects of High Doses of OROS Methylphenidate in Adolescents with ADHD
Paul G. Hammerness, M.D. Massachusetts General Hospital, Cambridge, MA
 
3.27
Metabolic Effects of Antipsychotics in Children (MEAC): Preliminary Results
Ginger E. Nicol, M.D. Washington University School of Medicine, St. Louis, MO
Dan Haupt, M.D.
Karen Flavin, R.N.
Martha Hessler, B.S.
Julie Schweiger, R.N.
Emily Hessler, B.S.
Michael Yingling, B.S.
Matthew Wilson, M.D.
John W. Newcomer, M.D. Washington University School of Medicine, St. Louis, MO
 
3.28
Psychosis in State Wards Treated with Stimulants
Michael W. Naylor, M.D. University of Illinois at Chicago, Chicago, IL
Christine V. Davidson, Ph.D. University of Illinois at Chicago, Chicago, IL
David B. Henry, Ph.D.
Amber R. Thompson, B.S.
Alice G. Gottschalk, R.N.
 
3.29
Impact of Comorbid Disruptive Disorders on Pharmacotherapy for ADHD in Medicaid-Insured Youth
Julie M. Zito, Ph.D. University of Maryland, Baltimore, MD
Satish Valluri, M.P.H.
Sarah D. Hundley, B.A. University of Maryland, Baltimore, MD
Daniel J. Safer, M.D. Johns Hopkins Medical Institutions, Baltimore, MD
James F. Gardner, Sc.M.
Mark S. Maneval, B.S.
James J. Korelitz, Ph.D.
Diane L. McNally, M.S.
Perdita Taylor-Zapata, M.D.
Donald R. Mattison, M.D.
 
3.30
National Trends in the Ambulatory Treatment of Youth with Anticonvulsant-Mood Stabilizers for Psychiatric Disorders
Julie M. Zito, Ph.D. University of Maryland, Baltimore, MD
Sarah D. Hundley, B.A. University of Maryland, Baltimore, MD
Daniel J. Safer, M.D. Johns Hopkins Medical Institutions, Baltimore, MD
 
3.31
Relationship of Blood Lead and Manganese Levels with Psychiatric Symptoms
Young-Hui Yang, M.D. Seoul National University Hospital, Seoul, Seoul
Soo-Churl Cho, M.D., Ph.D. Seoul National University Hospital, Chongro-Gu, Seoul, Seoul
Boong-Nyun Kim, M.D., Ph.D. Seoul National University, Seoul South Korea
Jae-Won Kim, M.D., Ph.D. Seoul National University Hospital, Seoul South Korea
Yun-Chul Hong, M.D., Ph.D.
Hee Jeong Yoo, M.D., Ph.D. Seoul National University, Bundang Hospital, Seongnam, Kyeonggi-do South Korea
Min-Sup Shin, Ph.D. Department of Child and Adolescent Psychiatry, College of Medicine, Seoul National University, Seoul South Korea
Soo-Young Bhang, M.D.
Yeni Kim, M.D., Ph.D. Seoul National University; Boramae Hospital, Seoul South Korea
 
3.32
Physical and Mental Disorder Comorbidity in a Nationally Representative Sample of U.S. Youth: IMPACT on Professional Health Service Use
Enrico Suardi, M.D. D.C. Department of Mental Health, St. Elizabeths Hospital, Washington, DC
He Jiang-Ping, M.S.
Srirangam S. Shreeram, M.D. District of Columbia Department of Mental Health, Vienna, VA
Kathleen R. Merikangas, Ph.D. National Institute of Mental Health, Bethesda, MD
 
3.33
Computer Addiction in Child Psychiatric Out Patients
Harjot Singh Sekhon, M.D. University of Virginia, Charlottesville, VA
Roger Burket, M.D. , Keswick, VA
Martha Mann, M.D. , Warrenton, VA
Aditya Sharma, M.D.
Sumit Anand, M.D.
Michelle Frieben, M.D. New River Valley Community Services, Blacksburg, VA
Adrienne Keller, Ph.D.
 
3.34
Predictive Factors of Parenting Behaviors: Results of a French Transversal Survey in 6 to 11 Year Old School Children
Isabelle E. Pitrou, M.D., M.S.C. Fondation MGEN pour la Santé Publique, Paris France
Taraneh Shojaei-Brosseau, M.D. MGEN Foundation, Paris, TX
Ashley Wazana, M.D. Montreal Childre's Hospital, Montreal, PQ
Fabien Gilbert, M.S.C. Fondation MGEN pour la Santé Publique, Paris France
Viviane Kovess-Masfety, M.D., Ph.D. Fondation MGEN pour la Santé Publique, Paris France
 
3.35
Maternal Depression and Weight Gain among School Age Children
Cristiane S. Duarte, M.P.H., Ph.D. Columbia University, New York, NY
Sa Shen, Ph.D. Columbia University/New York State Psychiatric Institute, New York, NY
Ping Wu, Ph.D. , New York, NY
Christina W. Hoven, DrPH
 
3.36
Validity and Reliability of the CBCL/1.5-5 Mexican Version
Lilia Albores-Gallo, M.D., Ph.D. Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaría de Salud., Mexico Mexico
Laura Hernández-Guzmán, Ph.D. National Autonomous Mexican University, Mexico City Mexico
Juan Antonio N/A Diaz-Pichardo, M.D. Child Psychiatry Hospital Doctor. Juan N. Navarro, Mexico City Mexico
Beatriz Cortes-Hernández Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaría de Salud, Mexico City Mexico
Cynthia Esperón-Vargas, B.A. Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaría de Salud, Mexico City Mexico
 
3.37
Trends in Assignment of Bipolar Diagnoses in a Sample of Illinois State Wards
Toya Clay, M.D. University of Illinois at Chicago, Chicago, IL
Jennifer Le, M.D. University of Illinois at Chicago, Chicago, IL
Mathias Lillig, M.D.
Maria Dahn, M.D. , Oak Park, IL
 
3.38
A Comparative Study of the Psychiatric Characteristics Between Adolescents with Minor Offenses and Normal Adolescents and Their Parents
Un-Sun Chung, M.D., Ph.D. Kyungpook National University Hospital, Daegu South Korea
 
3.39
CAN CBCL/1.5-5 Distinguish Between Autism and ADHD
Lilia Albores-Gallo, M.D., Ph.D. Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaría de Salud., Mexico Mexico
Laura Hernández-Guzmán, Ph.D. National Autonomous Mexican University, Mexico City Mexico
Juan Antonio Antonio Díaz-Pichardo, M.D. Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaria de Salud, Mexico City Mexico
Beatriz Cortes-Hernández Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaría de Salud, Mexico City Mexico
Cecilia Hasfura-Buenaga, B.A. Hospital Psiquiátrico Infantil Dr. Juan N. Navarro. Secretaria de Salud, Mexico City Mexico
 
3.40
Eating Disorder Prevention Program Randomized Controlled Trial at 12 Months Follow-up
Pedro M. Ruiz-Lázaro, Ph.D. Child Psychiatry Clinical Hospital-University of Zaragoza I+CS, Zaragoza, Aragón
Pilar Comet, R.N.
Ana I. Calvo, M.D.
Maite A. Zapata, Ph.D.
David Calvo, M.D.
Silvia Mabry, M.D.
Eva Villas, M.D.
 
3.41
Eating Disorders Prevalence in Early Adolescence: Spanish Multicenter Study
Pedro M. Ruiz-Lázaro, Ph.D. Child Psychiatry Clinical Hospital-University of Zaragoza I+CS, Zaragoza, Aragón
Pilar Comet, R.N.
Jesus Pérez, Ph.D.
José A. Gómez, Ph.D.
María Calado, Ph.D.
Marta Cebollada, Ph.D.
Maite A. Zapata, Ph.D.
Ana I. Calvo, M.D.
 
3.42
Comorbidity of Internet Addicted Children and Adolescents
Dong-Hyun Ahn Hanynag University Hospital, Seoul Korea
Jae-Young Lee, M.D.
Yang-Suk Kim, M.D.
Hyoun-Jeong Kim, M.D.
Seung-Ah Jung, Ph.D.
 
3.43
Substance Use and Psychopathology of CoA with Internet Addiction
Joung-Sook Ahn, M.D., Ph.D. Wonju College of Medicine; Yonsei University, Wonju, Gangwon-do
Min-Hyuk Kim, M.D.
Seongho Min, M.D.
Jongho Shin, M.D.
 
3.44
The Aggression Assessment: A Scale for Predicting Inpatient Pediatric Aggression
Drew Barzman, M.D. Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Michael T. Sorter, M.D. Children's Hospital Medical Center, Cincinnati, OH
Anita Goel
Melissa P. DelBello, M.D. University of Cincinnati College of Medicine, Cincinnati, OH
Kevin Stanford, M.P.H.
Robert A. Kowatch, M.D., Ph.D. Children's Hospital, Cincinnati, OH
Shannon N. Saldaña, M.S. , Cincinnati, OH
 
3.45
Screening Adolescents for Mental Health Problems in Primary Care
Mathilde M. Husky, Ph.D. New York State Psychiatric Institute, Columbia University, New York, NY
Kathleen Miller, R.N.
Leslie McGuire, M.S.W.
Laurie Flynn
Mark Olfson, M.D.
 
3.46
Exploring the Overlap Between Youth with Suicidal Ideation and Parental Recognition of Mental Health Need among a Sample of Homeless Families Residing in New York City Shelters
Orly Olshtain-Mann, Ph.D. Mount Sinai School of Medicine, New York, NY
William Bannon, Ph.D. Mount Sinai school of Medicine, New York, NY
Nisha Beharie, M.P.H. Mount Sinai school of Medicine, New York, NY
Mary McKay, Ph.D. Mount Sinai school of Medicine, New York, NY
 
3.48
Social Withdrawal in Fragile X Syndrome: Characterization by Factor Analysis
Dejan B. Budimirovic, M.D. Johns Hopkins University School of Medicine, Baltimore, MD
Walter E. Kaufmann, M.D.
 
3.49
Characterization of Social Withdrawal in Fragile X Syndrome by Factor Analysis
Dejan B. Budimirovic, M.D. Johns Hopkins University School of Medicine, Baltimore, MD
Walter E. Kaufmann, M.D.
 
3.50
Relationship Between Sensory Processing and Participation in Out-of-School Activities
Claudia L. Hilton, Ph.D. Washington University, St. Louis, MO
Patti D. LaVesser, Ph.D.
 
3.51
Executive Dysfunction in Autism Associated with ADHD--Not Autistic--Symptomatology
Deborah A. Pearson, Ph.D. University of Texas Medical School at Houston, Houston, TX
Katherine A. Loveland, Ph.D.
Cynthia Santos, M.D. University of Texas at Houston Medical School, Houston, TX
Charles Casat, M.D. Carolina NeuroSolutions, Charleston, SC
Michael G. Aman, Ph.D. Ohio State University, Columbus, OH
David M. Lane, Ph.D.
Christina Chen, M.D. , League City, TX
Ajinder Dhatt, M.D. , Houston, TX
Yvette Drake-McLin, M.D. , Pearland, TX
Iram Kazimi, M.D. , Sugar Land, TX
Susan W. Jerger, Ph.D.
Rosleen Mansour, M.A.
Meena Khowaja, B.A.
Perry Factor
Christopher Gonzales
Lynne A. Cleveland
 
3.52
Relationship Between Global and Component Aspects of ADHD and Autism
Deborah A. Pearson, Ph.D. Department of Psychiatry and Behavioral Sciences, Houston, TX
Cynthia Santos, M.D. University of Texas at Houston Medical School, Houston, TX
Katherine A. Loveland, Ph.D.
Charles Casat, M.D. Carolina NeuroSolutions, Charleston, SC
Michael G. Aman, Ph.D. Ohio State University, Columbus, OH
David M. Lane, Ph.D.
Susan W. Jerger, Ph.D.
Christina Chen, M.D. , League City, TX
Ajinder Dhatt, M.D. , Houston, TX
Yvette Drake-McLin, M.D. , Pearland, TX
Iram Kazimi, M.D. , Sugar Land, TX
Rosleen Mansour, M.A.
Meena Khowaja, B.A.
Perry Factor
Christopher Gonzales
Lynne A. Cleveland
 
3.53
A Double-Blind Placebo-Controlled Study of D-Cycloserine in Children with Autistic Disorder
David J. Posey, M.D., M.S. Riley Hospital for Children, Indianapolis, IN
Kimberly A. Stigler, M.D. Indiana University School of Medicine, Indianapolis, IN
Craig A. Erickson, M.D. Indiana University School of Medicine, Indianapolis, IN
Faouzi Azzouz, M.S.
Jennifer Mullett, R.N.
Jon T. Diener
Christopher J. McDougle, M.D. Indiana University School of Medicine, Indianapolis, IN
 
3.54
Cortical Maturation in Autism Spectrum Disorder
Armin Raznahan, MBBS Institute of Psychiatry, London United Kingdom
Roberto Toro, Ph.D. Brain and Body Centre, University of Nottingham
Eileen Daly, Ph.D. Department of Psychological Medicine, Section on Brain Maturation, Institute of Psychiatry, King's College London
Patrick F. Bolton, F.R.C.Psych., Ph.D. MRC Centre for Social Genetic and Developmental Psychiatry, Institute of Psychiatry, King's College London
Tomas Paus, M.D., Ph.D. Brain and Body Centre, University of Nottingham
Declan G. Murphy, M.D., F.R.C.Psych., MBBS Department of Psychological Medicine, Section on Brain Maturation, Institute of Psychiatry, King's College London
 
3.55
Psychiatric Co-Morbidity in Autistic Children and Psychological Distress of Their Parents
Norbert Skokauskas Jr., M.D., Ph.D. Trinity Centre for Health Sciences, St. Jame's Hospital,, Dublin Ireland
Louise Gallagher, MBChB, M.R.C.Psych., Ph.D. National Children's Hospital Tallaght, Dept. of Psychiatry Trinity College Dublin, Dublin Ireland
Jane Sanders, M.D.
Miriam Law, Ph.D.
 
3.56
Social Impairment and Symptoms of Anxiety and Aggression in a Community-Based Sample
Yanki Yazgan, M.D. Marmara University Hospital, Istanbul Turkey
Selin Unal
Ceyda Dedeoglu, M.A.
Beril Taskin, M.D.
 
3.57
Family- and Population-Based Association Studies of Monoamine Oxidase-a (MAOA) Gene and Autism Spectrum Disorders in Korea
Hee Jeong Yoo, M.D., Ph.D. Seoul National University, Bundang Hospital, Seongnam, Kyeonggi-do South Korea
In Hee Cho, M.D., Ph.D.
Soon Ae Kim, M.D., Ph.D.
Mira Park, Ph.D.
Soo-Churl Cho, M.D., Ph.D. Seoul National University Hospital, Chongro-Gu, Seoul, Seoul
Boong-Nyun Kim, M.D., Ph.D. Seoul National University, Seoul South Korea
Jae Won Kim, M.D., Ph.D.
Yeni Kim, M.D., Ph.D. Seoul National University; Boramae Hospital, Seoul South Korea
Young Hee Yang, M.D.
Ju Yeon Lee, M.D.
Geon-Ho Bahn, M.D., Ph.D. Kyung-Hee University Hospital, Seoul Korea
Young-Sik Lee, M.D., Ph.D. Department of Psychiatry Chung Ang University Hospital, Seoul South Korea
 
3.58
The Association of Neurocognitive Abnormalities and Sterol Deficits in Smith Lemli Opitz Syndrome
Alka Aneja, M.D. Johns Hopkins University School of Medicine, Lutherville Timonium, MD
Forbes Porter, M.D., Ph.D.
Elaine Tierney, M.D. Kennedy Krieger Institute, Baltimore, MD
 
3.59
Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder in Children and Adolescents (6 – 17 years old): Results from a Fixed Dose, Double-Blind, Randomized, Placebo-Controlled Trial
Randall Owen, M.D.
Ronald Marcus, M.D.
Michael G. Aman, Ph.D. Ohio State University, Columbus, OH
George Manos, Ph.D. Bristol-Myers Squibb, Wallingford, CT
Raymond Mankoski, M.D., Ph.D. Bristol-Myers Squibb, Plainsboro, NJ
Sheila Assuncao-Talbott, M.D., Ph.D.
Margaretta Nyilas, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Taro Iwamoto, Ph.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
William Carson, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Dan A. Oren, M.D. Bristol-Myers Squibb, Woodbridge, CT
 
3.60
Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial
Randall Owen, M.D.
Robert L. Findling, M.D. University Hospitals Case Medical Center, Cleveland, OH
Gabrielle A. Carlson, M.D. SUNY at Stony Brook, Stony Brook, NY
Margaretta Nyilas, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Taro Iwamoto, Ph.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Raymond Mankoski, M.D., Ph.D. Bristol-Myers Squibb, Plainsboro, NJ
Sheila Assunção-Talbott, M.D., Ph.D. Bristol-Myers Squibb, Plainsboro, NJ
William Carson, M.D. Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ
Dan A. Oren, M.D. Bristol-Myers Squibb, Woodbridge, CT
See more of: New Research Poster